Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib

MeSH terms

• Antibodies, Monoclonal, Murine-Derived / adverse effects
• Antibodies, Monoclonal, Murine-Derived / therapeutic use
• Antimetabolites, Antineoplastic / adverse effects
• Antimetabolites, Antineoplastic / therapeutic use
• Antineoplastic Agents / therapeutic use*
• Cladribine / adverse effects
• Cladribine / therapeutic use
• Combined Modality Therapy
• Compassionate Use Trials
• Drug Resistance, Neoplasm
• Humans
• Imidazoles / therapeutic use*
• Leukemia, Hairy Cell / blood
• Leukemia, Hairy Cell / drug therapy*
• Leukemia, Hairy Cell / surgery
• Male
• Middle Aged
• Molecular Targeted Therapy*
• Mutation, Missense
• Neoplasm Proteins / antagonists & inhibitors*
• Neoplasm Proteins / genetics
• Neutropenia / chemically induced
• Neutropenia / complications
• Oximes / therapeutic use*
• Point Mutation
• Protein Kinase Inhibitors / therapeutic use*
• Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
• Proto-Oncogene Proteins B-raf / genetics
• Pulmonary Aspergillosis / etiology
• Remission Induction
• Rituximab
• Salvage Therapy*
• Splenectomy